Biotech, cancer, deals Luke Timmerman wrote: The recession will surely kill off some biotech companies that lack hard cash and the hard data that shows their experimental drugs can improve patients’ lives. But after I heard Seattle Genetics CEO Clay Siegall tell the story of how his company ra...

Biotech, Hepatitis C, Life Sciences Luke Timmerman wrote: An early peek at data from Anadys Pharmaceuticals (NASDAQ: ANDS) suggests the company may have a promising new drug in the works for hepatitis C. The San Diego-based biotech is announcing results today from the first eight patients with the c...

Biotech, people, startups Luke Timmerman wrote: It’s cold outside, so I was a little bummed there was no actual fire at an event last night billed as a “fireside chat.” This get-together actually took some time to warm up (pun intended). But once it got rolling, three of the most e...